Lydall Company Overview, Contact Details & Competitors

Q: What is Lydall's official website and social media links?

Lydall's official website is lydall.com. Lydall has social profiles on LinkedIn.

Q: How many employees does Lydall have currently?

Lydall has approximately 1K employees.

Q: What technology does Lydall use?

Lydall's tech stack includes Cognex, C++, Skype for Business, Pure Storage, Apple iCloud Mail.

Insights

Gathering insights about Lydall…

Similar companies to Lydall

Lydall Tech Stack

Lydall uses 8 technology products and services including Microsoft SharePoint, Oracle, Pure Storage, and more. Explore Lydall's tech stack below.

Microsoft SharePoint
Content Management System
Oracle
Enterprise
Pure Storage
Enterprise Data Storage
Covisint
IT Infrastructure
Red Hat
Operating Systems
Microsoft Azure
Platform As A Service
VMware
Virtualisation Software
iCheck
Web Tools And Plugins

Media & News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.
Nov 18, 2025 | www.globenewswire.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.
Nov 09, 2025 | www.businesswire.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial.
Nov 08, 2025 | www.businesswire.com
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models
Oct 09, 2025 | www.globenewswire.com
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal.
Aug 30, 2025 | www.businesswire.com
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.i ii “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination with different doses of a statin, will make it easier for physicians to ta.
Aug 30, 2025 | www.businesswire.com
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.
Aug 25, 2025 | www.prnewswire.com

Lydall's Email Address Formats

Lydall uses at least 1 format(s):

Lydall Email Formats	Example	Percentage
FLast@lydall.com	JDoe@lydall.com	92%
First.Last@lydall.com	John.Doe@lydall.com	6%
LFirst@lydall.com	DJohn@lydall.com	1%
LastF@lydall.com	DoeJ@lydall.com	1%

Frequently Asked Questions

What is Lydall's phone number?

You can contact Lydall's main corporate office by phone at

+1-860-646-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Lydall's stock symbol?

Lydall is a publicly traded company; the company's stock symbol is LDL.

What is Lydall's official website and social media links?

Lydall's official website is lydall.com and has social profiles on LinkedIn.

How much revenue does Lydall generate?

As of December 2025, Lydall's annual revenue is estimated to be $764M.

What is Lydall's NAICS code?

Lydall's NAICS code is 3332 - Industrial Machinery Manufacturing.

How many employees does Lydall have currently?

As of December 2025, Lydall has approximately 1K employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Information Officer: J. T.Chief Audit Executive: G. D.Vp Associate General Counsel And Chief Compliance Officer At Vontier: H. S.. Explore Lydall's employee directory with LeadIQ.

What industry does Lydall belong to?

Lydall operates in the Industrial Machinery Manufacturing industry.

What technology does Lydall use?

Lydall's tech stack includes Microsoft SharePointOraclePure StorageCovisintRed HatMicrosoft AzureVMwareiCheck.

What is Lydall's email format?

Lydall's email format typically follows the pattern of FLast@lydall.com. Find more Lydall email formats with LeadIQ.

Insights

Similar companies to Lydall

Ingersoll Rand

Aearo Technologies

Lydall Tech Stack

Media & News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C

Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

Lydall's Email Address Formats

Frequently Asked Questions

What is Lydall's phone number?

What is Lydall's stock symbol?

What is Lydall's official website and social media links?

How much revenue does Lydall generate?

What is Lydall's NAICS code?

How many employees does Lydall have currently?

What industry does Lydall belong to?

What technology does Lydall use?

What is Lydall's email format?

Lydall

Company Overview

Media & News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?